Team

Driven by Purpose

Nuvalent has assembled a world-class team with deep expertise in structure-based drug discovery, oncology drug development and building new companies.

Nuvalent Team
Ruth Adams
Ruth Adams
Clinical Operations
Ruth Adams
Ruth Adams
Clinical Operations

Ruth is a clinical research professional who brings to the Nuvalent team more than 20 years of experience in oncology drug development spanning across research and development. She joined the team in November 2020 and is currently responsible for oversight of trial execution, clinical compliance, and outsourcing strategy.

Before joining Nuvalent in this role, Ruth was an independent clinical operations consultant, where she collaborated closely with the Nuvalent team. Prior to this, Ruth served as head of clinical operations at Vigeo Therapeutics where she was responsible for leading their inaugural oncology study. During her tenure at BeiGene, Ruth was accountable for the operational program strategy, oversight and execution of US led global hematology studies. At Infinity Pharmaceuticals Ruth managed their registrational study and acted as the NDA submission SME for a program that later resulted in FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Takeda Pharmaceuticals, Ruth held a position in the early phase oncology group where she managed multiple first-in-human studies. Before her transition to clinical operations Ruth was an accomplished medicinal chemist and held positions at Millennium Pharmaceuticals and Cambridge Discovery Chemistry, focusing on the design and synthesis of lead oncology compounds.

Ruth earned her bachelor’s degree in chemistry at The University of Southampton, UK.

Kristin Andrews, PhD
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Kristin Andrews, PhD
Computational Chemistry
Alex Balcom
Alex Balcom, MBA, CPA
Chief Financial Officer
Alex Balcom
Alex Balcom, MBA, CPA
Chief Financial Officer

Alex joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial and operational experience in the biotechnology industry to her role.

Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she was responsible for strategic planning, finance and accounting. During her time at SQZ Biotechnologies, she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Before joining SQZ, Alex served as Corporate Controller at Agios Pharmaceuticals, where she built the finance and accounting teams and contributed to the company’s strategic financing efforts, raising more than $700 million in equity financing, including playing a key role in the 2013 initial public offering. Alex was responsible for all financial functions of the company including strategic planning, treasury, tax, finance and accounting. Earlier in her career, Alex held positions at both Molecular Insight Pharmaceuticals, a publicly-traded oncology company, acquired in 2013 and Coley Pharmaceuticals, a publicly-traded company developing immunotherapies for cancer and other disease areas, acquired by Pfizer in 2007.  

Alex earned her B.B.A in finance from the University of Massachusetts, Amherst and her M.B.A from Boston College. Alex is also a certified public accountant in Massachusetts.

Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Paula Chubet
Legal
Paula Chubet
Legal
Allison Ciborowski
Quality Assurance
Allison Ciborowski
Quality Assurance
Shannon Dauksis, PharmD
Program Management
Shannon Dauksis, PharmD
Program Management
Jenn Fairbanks
Clinical Operations
Jenn Fairbanks
Clinical Operations
Baudouin Gerard, PhD
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Baudouin Gerard, PhD
Medicinal Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Chemistry

Joshua joined the Nuvalent team in June 2018. As Vice President of Nuvalent’s discovery chemistry program, Joshua’s team works with scientific collaborators both in the United States and around the world to identify optimized, small-molecule drug candidates.

Joshua brings over 15 years of drug discovery experience spanning the fields of immunology, nephrology, proteopathy, and oncology. Prior to joining Nuvalent, he was a Senior Principal Scientist of Medical Chemistry at Proteostasis Therapeutics where he worked on high-throughput phenotypic screens and subsequent discovery programs in protein-folding diseases such as Cystic Fibrosis. While at Proteostasis he additionally served as head of the Compound Management group and spearheaded Discovery Informatics. Prior to Proteostasis, he held multiple positions at Boehringer-Ingelheim Pharmaceuticals, most recently serving as Principal Scientist. At Boehringer he worked on a wide range of targets including: LFA-1, S1P1, RORC, BTK, LPA1, and TRPC6.

Joshua earned his PhD in Organic Chemistry from Stanford University.

Tina Kehrig
Clinical Operations
Tina Kehrig
Clinical Operations
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Jason Kropp
Jason Kropp
Pharmaceutical Development
Jason Kropp
Jason Kropp
Pharmaceutical Development
Benjamin Lane, PhD
Benjamin Lane, PhD
Pharmaceutical Development
Benjamin Lane, PhD
Benjamin Lane, PhD
Pharmaceutical Development

For over 16 years, Ben has contributed to the development of pre-clinical through commercial programs at both large and small biotech companies. He joined Nuvalent in October 2020 as the Vice President of Pharmaceutical Development.

Ben started out as a process chemist supporting small molecule development at Biogen, where he helped expand the internal research capabilities and start the first internal kilo-lab. Biogen afforded him the opportunity to quickly become the technical drug substance lead for several Phase 1 and 2 programs in both the neurology and oncology spaces. Following his love for complex synthetic challenges, Ben transitioned to the Process Chemistry group at Infinity Pharmaceuticals to work on the scale up of several semisynthetic natural products, including Saridegib. While serving as the duvelisib drug substance SME, Ben led the process chemistry efforts from drug candidate nomination into process validation. This later resulted in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Agios, Ben led the process chemistry group, which was responsible for pre-clinical to commercial drug substance development and manufacturing. Most notably, Ben has been the Technical Operations asset manager for the Mitapivat program for the treatment of hemolytic anemias and has seen the program through from Phase 1 through process validation. Ben earned his degree PhD from Texas A&M University and held a postdoctoral position at Columbia University. 

Lori Lavoie
Human Resources
Lori Lavoie
Human Resources
Lidya Le
Clinical Operations
Lidya Le
Clinical Operations
Christian Martin
Translational Development
Christian Martin
Translational Development
Stephen McNamara
Finance
Stephen McNamara
Finance
Scot Mente, PhD
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Scot Mente, PhD
Computational Chemistry
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer

Deborah (Deb) Miller, Ph.D., J.D., joined Nuvalent as Chief Legal Officer in June 2021 and is responsible for legal and human resources. She brings more than 20 years of senior leadership and global legal expertise across the entire pharmaceutical lifecycle from early discovery though litigation.

Prior to joining Nuvalent, she most recently served as Senior Vice President, Deputy General Counsel and Chief IP Counsel for Sumitomo Dainippon Pharma America (SDPA), a shared services company supporting affiliates of the Sumitomo Dainippon Pharma Group including Sunovion Pharmaceuticals Inc. and SDP Oncology. At SDPA, she led global IP strategy, IP diligence, as well as various contract dispute matters and business development transactions and was instrumental in building and enforcing global IP portfolios for over 30 oncologic, neurologic, psychiatric, and respiratory products, including LATUDA®, KYNMOBI®, APTIOM®, and LONHALA® MAGNAIR®.

Earlier in her career, Deb served as Deputy General Counsel and Chief Patent Counsel at Infinity Pharmaceuticals where she was responsible for developing the IP strategy of various oncology products and helped secure multiple strategic partnerships. In addition, she served as Corporate Counsel at Sepracor (now Sunovion) where she managed the litigation of LUNESTA® and developed the IP for various CNS and respiratory products. She began her legal career in private practice at Nutter McClennen & Fish.

Deb earned her Bachelor’s degree in chemistry from Swarthmore College, Master’s in Medical Sciences from Harvard Medical School, Ph.D. in biological chemistry and molecular pharmacology from Harvard University, and J.D. from Suffolk University Law School.

Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
Darlene Noci, ALM
Darlene Noci, ALM
Product Development & Regulatory Affairs
Darlene Noci, ALM
Darlene Noci, ALM
Product Development & Regulatory Affairs

Darlene Noci brings to Nuvalent over 20 years of experience as an accomplished global product development leader specializing in global regulatory affairs and strategic oversight of early and late-stage programs.

Throughout her career, Darlene contributed to several successful drug approvals, including Fabrazyme®, Mozobil®, Clolar®/Evoltra®, and Bavencio®. Prior to founding her own regulatory consulting firm in 2018, Darlene served as Vice President, Regulatory Affairs and Quality Assurance at X4 Pharmaceuticals. Prior to X4, Darlene served as Global Regulatory Lead Strategist, Immuno-Oncology at EMD Serono, the North America biopharma business of Merck KgaA, Darmstadt, Germany where she led the global regulatory strategy and portfolio for Bavencio®, the company’s anti-programmed death-ligand 1 (PDL-1) antibody. In this role, she was instrumental in the global clinical development in record time to a proof of concept spanning more than 10 solid tumor indications, including non-small cell lung cancer and urothelial carcinoma. Darlene drove the team responsible for securing Bavencio’s Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation, which led to accelerated approval for the treatment of patients with Merkel Cell Carcinoma. Darlene also served on the joint steering committee with Pfizer. Prior to EMD Serono, she held various regulatory and team leadership positions with increasing responsibility in oncology and rare disease at several companies including Infinity, Sanofi, and Genzyme. She gives credit to her mentors at Genzyme, where she spent 14 years, inspired by leaders driven by science and passion for bringing much needed therapies to patients.

Darlene earned her Master’s degree in Government from Harvard University.

Henry Pelish, PhD
Henry Pelish, PhD
Biology
Henry Pelish, PhD
Henry Pelish, PhD
Biology

Henry is a multidisciplinary scientist skilled in cancer biology, chemical biology and organic synthesis. He contributed to the creation of Nuvalent and joined full-time in 2018. In July 2020, he was promoted to Vice President.

Henry’s career has spanned multiple industry and academic appointments. Prior to joining Nuvalent, Henry was a group leader in the laboratory of Professor Matthew Shair at Harvard University. In that role, he built and led a team that discovered a new target, mechanism of action and therapeutic opportunity for treatment of acute myeloid leukemia. In parallel, he spearheaded a drug discovery program that culminated in a licensing deal and research agreement between Harvard and Merck in 2016, and subsequently served as a member of the Harvard-Merck Joint Research Committee.

Henry earned a PhD in Chemistry from Harvard University and is an avid runner and swimmer.

James Porter, PhD
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer

Jim is an accomplished cancer researcher with two decades of oncology drug development experience. He joined Nuvalent during company creation in 2018 and became Chief Executive Officer and named to the Nuvalent Board of Directors in January 2020.

Jim began his career at Infinity Pharmaceuticals as one of the initial scientists to join the company in its first year of operation. Over the course of his 15 years at Infinity, he obtained a wide array of company building experience, helping to build the infrastructure and leading high-performing teams in medicinal chemistry, pharmaceutical development, alliance management, program management, and product development. At Infinity, he contributed to the research and development programs of six different compounds entering clinical trials, helped secure business development agreements and lead corporate alliances for multiple development compounds, and held increasing roles of responsibility up to Vice President of Product Development. As the duvelisib Product Development team leader, Jim led a cross-functional development team from development candidate nomination through NDA submission, resulting in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. Jim led the transition, Product Development team, and NDA submission at Verastem Oncology upon the company’s acquisition of the duvelisib program during Phase 3 clinical development. He earned his BA in chemistry at the College of the Holy Cross and PhD in organic chemistry from Boston College.

Gosia Riley
Clinical Operations
Gosia Riley
Clinical Operations
John Soglia, PhD
John Soglia, PhD
Translational Development
John Soglia, PhD
John Soglia, PhD
Translational Development

John joined Nuvalent in January 2020 and leads the strategy and execution of translational development activities of the company’s lead programs, including ADME, nonclinical safety and clinical pharmacology.

John began his career at Pfizer in Groton, CT. While at Pfizer, John developed a novel in vitro ADME/safety assay which was used by the company globally to help reduce drug safety risk. In addition to his research, John was a member of the Pfizer hepatotoxicity working group and global hepatotoxicity reduction initiative. In 2005, John was awarded the Pfizer Global Research and Development Achievement Award for his impact, cross functional collaboration and contributions to the company. John then moved to GlaxoSmithKline in North Carolina to become Chief Scientist in the infectious diseases center of emphasis for drug discovery (CEDD). In this role, John served as a senior DMPK project leader, group supervisor and prepared ADME/PK packages for IND submission. At GSK, John was also a member of the global drug induced liver injury (DILI) taskforce, leveraging his experience to reduce drug attrition due to hepatotoxicity. Following his time in pharma, John joined Infinity Pharmaceuticals as head of DMPK in 2012. While at Infinity, John was the DMPK lead on the duvelisib Product Development Team, responsible for preparing the ADME/PK package for NDA submission. John was also the eganelisib (IPI-549) Product Development Team leader, successfully leading the cross-functional team to IND submission and into early clinical development. Most recently John was at Decibel Therapeutics where, in addition to leading the DMPK, clinical pharmacology and regulated bioanalytical functions, he was the early Product Development Scientific Lead on the DB-020 program which is currently in clinical trials for the prevention of chemotherapy induced hearing loss.

John earned his PhD in Chemistry from Northeastern University.

Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Anupong Tangpeerachaikul, PhD
Anupong Tangpeerachaikul, PhD
Biology
Anupong Tangpeerachaikul, PhD
Anupong Tangpeerachaikul, PhD
Biology
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer

Christopher (Chris) Turner, M.D. is an experienced oncology drug developer and executive with over 20 years of clinical and pharmaceutical experience in both early and late stage oncology drug development. He joined Nuvalent in March 2021 as Chief Medical Officer.

Before joining Nuvalent, Dr. Turner was Vice President of Clinical Development at Blueprint Medicines, where he oversaw the development and approval of kinase inhibitor GAVRETO™ (pralsetinib) in RET fusion positive non-small cell lung cancer (NSCLC) and RET altered thyroid cancer. Additionally, Dr. Turner oversaw development programs targeting the FGFR4 kinase and EGFR with emergent resistance mutations.

Dr. Turner previously led the development of novel ADC and immune-oncology pipeline compounds at Celldex Therapeutics, and the clinical development at Ariad Pharmaceuticals of two kinase inhibitor therapies that have since been approved for patients with cancer, ICLUSIG® (ponatinib) for patients with chronic myeloid leukemia, and ALUNBRIG® (brigatinib) for patients with ALK-positive NSCLC.

Prior to that, Dr. Turner was Director of the Pediatric Neuro-Oncology Outcomes Clinic at the Dana-Farber Cancer Institute/Children’s Hospital Boston and an Instructor of Pediatrics at Harvard Medical School where he treated children and young adults with brain tumors.

Dr. Turner is double board certified in both Pediatrics and Pediatric Hematology and Oncology and is a Fellow of the American Academy of Pediatrics. He received his M.D. from the University of Rochester School of Medicine and Dentistry in Rochester, New York. He completed fellowships in both Pediatric Hematology/Oncology and Pediatric Neuro-Oncology at Duke University Medical Center in Durham, North Carolina.

Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
Ruth Adams
Ruth Adams
Vice President, Clinical Operations
Ruth Adams
Ruth Adams
Vice President, Clinical Operations

Ruth is a clinical research professional who brings to the Nuvalent team more than 20 years of experience in oncology drug development spanning across research and development. She joined the team in November 2020 and is currently responsible for oversight of trial execution, clinical compliance, and outsourcing strategy.

Before joining Nuvalent in this role, Ruth was an independent clinical operations consultant, where she collaborated closely with the Nuvalent team. Prior to this, Ruth served as head of clinical operations at Vigeo Therapeutics where she was responsible for leading their inaugural oncology study. During her tenure at BeiGene, Ruth was accountable for the operational program strategy, oversight and execution of US led global hematology studies. At Infinity Pharmaceuticals Ruth managed their registrational study and acted as the NDA submission SME for a program that later resulted in FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Takeda Pharmaceuticals, Ruth held a position in the early phase oncology group where she managed multiple first-in-human studies. Before her transition to clinical operations Ruth was an accomplished medicinal chemist and held positions at Millennium Pharmaceuticals and Cambridge Discovery Chemistry, focusing on the design and synthesis of lead oncology compounds.

Ruth earned her bachelor’s degree in chemistry at The University of Southampton, UK.

Alex Balcom
Alex Balcom, MBA, CPA
Chief Financial Officer
Alex Balcom
Alex Balcom, MBA, CPA
Chief Financial Officer

Alex joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial and operational experience in the biotechnology industry to her role.

Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she was responsible for strategic planning, finance and accounting. During her time at SQZ Biotechnologies, she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Before joining SQZ, Alex served as Corporate Controller at Agios Pharmaceuticals, where she built the finance and accounting teams and contributed to the company’s strategic financing efforts, raising more than $700 million in equity financing, including playing a key role in the 2013 initial public offering. Alex was responsible for all financial functions of the company including strategic planning, treasury, tax, finance and accounting. Earlier in her career, Alex held positions at both Molecular Insight Pharmaceuticals, a publicly-traded oncology company, acquired in 2013 and Coley Pharmaceuticals, a publicly-traded company developing immunotherapies for cancer and other disease areas, acquired by Pfizer in 2007.  

Alex earned her B.B.A in finance from the University of Massachusetts, Amherst and her M.B.A from Boston College. Alex is also a certified public accountant in Massachusetts.

Joshua Horan, PhD
Joshua Horan, PhD
Vice President, Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Vice President, Chemistry

Joshua joined the Nuvalent team in June 2018. As Vice President of Nuvalent’s discovery chemistry program, Joshua’s team works with scientific collaborators both in the United States and around the world to identify optimized, small-molecule drug candidates.

Joshua brings over 15 years of drug discovery experience spanning the fields of immunology, nephrology, proteopathy, and oncology. Prior to joining Nuvalent, he was a Senior Principal Scientist of Medical Chemistry at Proteostasis Therapeutics where he worked on high-throughput phenotypic screens and subsequent discovery programs in protein-folding diseases such as Cystic Fibrosis. While at Proteostasis he additionally served as head of the Compound Management group and spearheaded Discovery Informatics. Prior to Proteostasis, he held multiple positions at Boehringer-Ingelheim Pharmaceuticals, most recently serving as Principal Scientist. At Boehringer he worked on a wide range of targets including: LFA-1, S1P1, RORC, BTK, LPA1, and TRPC6.

Joshua earned his PhD in Organic Chemistry from Stanford University.

Benjamin Lane, PhD
Benjamin Lane, PhD
VP, Pharmaceutical Development
Benjamin Lane, PhD
Benjamin Lane, PhD
VP, Pharmaceutical Development

For over 16 years, Ben has contributed to the development of pre-clinical through commercial programs at both large and small biotech companies. He joined Nuvalent in October 2020 as the Vice President of Pharmaceutical Development.

Ben started out as a process chemist supporting small molecule development at Biogen, where he helped expand the internal research capabilities and start the first internal kilo-lab. Biogen afforded him the opportunity to quickly become the technical drug substance lead for several Phase 1 and 2 programs in both the neurology and oncology spaces. Following his love for complex synthetic challenges, Ben transitioned to the Process Chemistry group at Infinity Pharmaceuticals to work on the scale up of several semisynthetic natural products, including Saridegib. While serving as the duvelisib drug substance SME, Ben led the process chemistry efforts from drug candidate nomination into process validation. This later resulted in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Agios, Ben led the process chemistry group, which was responsible for pre-clinical to commercial drug substance development and manufacturing. Most notably, Ben has been the Technical Operations asset manager for the Mitapivat program for the treatment of hemolytic anemias and has seen the program through from Phase 1 through process validation. Ben earned his degree PhD from Texas A&M University and held a postdoctoral position at Columbia University. 

Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer

Deborah (Deb) Miller, Ph.D., J.D., joined Nuvalent as Chief Legal Officer in June 2021 and is responsible for legal and human resources. She brings more than 20 years of senior leadership and global legal expertise across the entire pharmaceutical lifecycle from early discovery though litigation.

Prior to joining Nuvalent, she most recently served as Senior Vice President, Deputy General Counsel and Chief IP Counsel for Sumitomo Dainippon Pharma America (SDPA), a shared services company supporting affiliates of the Sumitomo Dainippon Pharma Group including Sunovion Pharmaceuticals Inc. and SDP Oncology. At SDPA, she led global IP strategy, IP diligence, as well as various contract dispute matters and business development transactions and was instrumental in building and enforcing global IP portfolios for over 30 oncologic, neurologic, psychiatric, and respiratory products, including LATUDA®, KYNMOBI®, APTIOM®, and LONHALA® MAGNAIR®.

Earlier in her career, Deb served as Deputy General Counsel and Chief Patent Counsel at Infinity Pharmaceuticals where she was responsible for developing the IP strategy of various oncology products and helped secure multiple strategic partnerships. In addition, she served as Corporate Counsel at Sepracor (now Sunovion) where she managed the litigation of LUNESTA® and developed the IP for various CNS and respiratory products. She began her legal career in private practice at Nutter McClennen & Fish.

Deb earned her Bachelor’s degree in chemistry from Swarthmore College, Master’s in Medical Sciences from Harvard Medical School, Ph.D. in biological chemistry and molecular pharmacology from Harvard University, and J.D. from Suffolk University Law School.

Darlene Noci, ALM
Darlene Noci, ALM
SVP, Product Development & Regulatory Affairs
Darlene Noci, ALM
Darlene Noci, ALM
SVP, Product Development & Regulatory Affairs

Darlene Noci brings to Nuvalent over 20 years of experience as an accomplished global product development leader specializing in global regulatory affairs and strategic oversight of early and late-stage programs.

Throughout her career, Darlene contributed to several successful drug approvals, including Fabrazyme®, Mozobil®, Clolar®/Evoltra®, and Bavencio®. Prior to founding her own regulatory consulting firm in 2018, Darlene served as Vice President, Regulatory Affairs and Quality Assurance at X4 Pharmaceuticals. Prior to X4, Darlene served as Global Regulatory Lead Strategist, Immuno-Oncology at EMD Serono, the North America biopharma business of Merck KgaA, Darmstadt, Germany where she led the global regulatory strategy and portfolio for Bavencio®, the company’s anti-programmed death-ligand 1 (PDL-1) antibody. In this role, she was instrumental in the global clinical development in record time to a proof of concept spanning more than 10 solid tumor indications, including non-small cell lung cancer and urothelial carcinoma. Darlene drove the team responsible for securing Bavencio’s Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation, which led to accelerated approval for the treatment of patients with Merkel Cell Carcinoma. Darlene also served on the joint steering committee with Pfizer. Prior to EMD Serono, she held various regulatory and team leadership positions with increasing responsibility in oncology and rare disease at several companies including Infinity, Sanofi, and Genzyme. She gives credit to her mentors at Genzyme, where she spent 14 years, inspired by leaders driven by science and passion for bringing much needed therapies to patients.

Darlene earned her Master’s degree in Government from Harvard University.

Henry Pelish, PhD
Henry Pelish, PhD
Vice President, Biology
Henry Pelish, PhD
Henry Pelish, PhD
Vice President, Biology

Henry is a multidisciplinary scientist skilled in cancer biology, chemical biology and organic synthesis. He contributed to the creation of Nuvalent and joined full-time in 2018. In July 2020, he was promoted to Vice President.

Henry’s career has spanned multiple industry and academic appointments. Prior to joining Nuvalent, Henry was a group leader in the laboratory of Professor Matthew Shair at Harvard University. In that role, he built and led a team that discovered a new target, mechanism of action and therapeutic opportunity for treatment of acute myeloid leukemia. In parallel, he spearheaded a drug discovery program that culminated in a licensing deal and research agreement between Harvard and Merck in 2016, and subsequently served as a member of the Harvard-Merck Joint Research Committee.

Henry earned a PhD in Chemistry from Harvard University and is an avid runner and swimmer.

James Porter, PhD
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer

Jim is an accomplished cancer researcher with two decades of oncology drug development experience. He joined Nuvalent during company creation in 2018 and became Chief Executive Officer and named to the Nuvalent Board of Directors in January 2020.

Jim began his career at Infinity Pharmaceuticals as one of the initial scientists to join the company in its first year of operation. Over the course of his 15 years at Infinity, he obtained a wide array of company building experience, helping to build the infrastructure and leading high-performing teams in medicinal chemistry, pharmaceutical development, alliance management, program management, and product development. At Infinity, he contributed to the research and development programs of six different compounds entering clinical trials, helped secure business development agreements and lead corporate alliances for multiple development compounds, and held increasing roles of responsibility up to Vice President of Product Development. As the duvelisib Product Development team leader, Jim led a cross-functional development team from development candidate nomination through NDA submission, resulting in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. Jim led the transition, Product Development team, and NDA submission at Verastem Oncology upon the company’s acquisition of the duvelisib program during Phase 3 clinical development. He earned his BA in chemistry at the College of the Holy Cross and PhD in organic chemistry from Boston College.

John Soglia, PhD
John Soglia, PhD
Vice President, Translational Development
John Soglia, PhD
John Soglia, PhD
Vice President, Translational Development

John joined Nuvalent in January 2020 and leads the strategy and execution of translational development activities of the company’s lead programs, including ADME, nonclinical safety and clinical pharmacology.

John began his career at Pfizer in Groton, CT. While at Pfizer, John developed a novel in vitro ADME/safety assay which was used by the company globally to help reduce drug safety risk. In addition to his research, John was a member of the Pfizer hepatotoxicity working group and global hepatotoxicity reduction initiative. In 2005, John was awarded the Pfizer Global Research and Development Achievement Award for his impact, cross functional collaboration and contributions to the company. John then moved to GlaxoSmithKline in North Carolina to become Chief Scientist in the infectious diseases center of emphasis for drug discovery (CEDD). In this role, John served as a senior DMPK project leader, group supervisor and prepared ADME/PK packages for IND submission. At GSK, John was also a member of the global drug induced liver injury (DILI) taskforce, leveraging his experience to reduce drug attrition due to hepatotoxicity. Following his time in pharma, John joined Infinity Pharmaceuticals as head of DMPK in 2012. While at Infinity, John was the DMPK lead on the duvelisib Product Development Team, responsible for preparing the ADME/PK package for NDA submission. John was also the eganelisib (IPI-549) Product Development Team leader, successfully leading the cross-functional team to IND submission and into early clinical development. Most recently John was at Decibel Therapeutics where, in addition to leading the DMPK, clinical pharmacology and regulated bioanalytical functions, he was the early Product Development Scientific Lead on the DB-020 program which is currently in clinical trials for the prevention of chemotherapy induced hearing loss.

John earned his PhD in Chemistry from Northeastern University.

Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer

Christopher (Chris) Turner, M.D. is an experienced oncology drug developer and executive with over 20 years of clinical and pharmaceutical experience in both early and late stage oncology drug development. He joined Nuvalent in March 2021 as Chief Medical Officer.

Before joining Nuvalent, Dr. Turner was Vice President of Clinical Development at Blueprint Medicines, where he oversaw the development and approval of kinase inhibitor GAVRETO™ (pralsetinib) in RET fusion positive non-small cell lung cancer (NSCLC) and RET altered thyroid cancer. Additionally, Dr. Turner oversaw development programs targeting the FGFR4 kinase and EGFR with emergent resistance mutations.

Dr. Turner previously led the development of novel ADC and immune-oncology pipeline compounds at Celldex Therapeutics, and the clinical development at Ariad Pharmaceuticals of two kinase inhibitor therapies that have since been approved for patients with cancer, ICLUSIG® (ponatinib) for patients with chronic myeloid leukemia, and ALUNBRIG® (brigatinib) for patients with ALK-positive NSCLC.

Prior to that, Dr. Turner was Director of the Pediatric Neuro-Oncology Outcomes Clinic at the Dana-Farber Cancer Institute/Children’s Hospital Boston and an Instructor of Pediatrics at Harvard Medical School where he treated children and young adults with brain tumors.

Dr. Turner is double board certified in both Pediatrics and Pediatric Hematology and Oncology and is a Fellow of the American Academy of Pediatrics. He received his M.D. from the University of Rochester School of Medicine and Dentistry in Rochester, New York. He completed fellowships in both Pediatric Hematology/Oncology and Pediatric Neuro-Oncology at Duke University Medical Center in Durham, North Carolina.

James Porter, PhD
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer

Jim is an accomplished cancer researcher with two decades of oncology drug development experience. He joined Nuvalent during company creation in 2018 and became Chief Executive Officer and named to the Nuvalent Board of Directors in January 2020.

Jim began his career at Infinity Pharmaceuticals as one of the initial scientists to join the company in its first year of operation. Over the course of his 15 years at Infinity, he obtained a wide array of company building experience, helping to build the infrastructure and leading high-performing teams in medicinal chemistry, pharmaceutical development, alliance management, program management, and product development. At Infinity, he contributed to the research and development programs of six different compounds entering clinical trials, helped secure business development agreements and lead corporate alliances for multiple development compounds, and held increasing roles of responsibility up to Vice President of Product Development. As the duvelisib Product Development team leader, Jim led a cross-functional development team from development candidate nomination through NDA submission, resulting in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. Jim led the transition, Product Development team, and NDA submission at Verastem Oncology upon the company’s acquisition of the duvelisib program during Phase 3 clinical development. He earned his BA in chemistry at the College of the Holy Cross and PhD in organic chemistry from Boston College.

Matthew D. Shair, PhD
Founder, Head Scientific Advisor
Matthew D. Shair, PhD
Founder, Head Scientific Advisor

Matt is a world-leading chemical biologist and organic chemist who has made important contributions to the discovery of new therapeutic targets, to understanding their mechanism and to the development of small molecules to perturb their function. Matt conceived of Nuvalent and in 2017 he founded the company with Deerfield Management.

Matt is a Professor in the Department of Chemistry and Chemical Biology at Harvard University as well as an affiliate of the Broad Institute and the Harvard Stem Cell Institute. Matt and his lab at Harvard have made critical strides in target-oriented synthesis of complex molecules including syntheses of CP-263,114, longithorone and cortistatin A. His lab helped pioneer diversity-oriented synthesis and they were amongst the first to combine it with cell-based phenotypic screening to identify new compounds with novel activities, including the discovery of the Cdc42 inhibitor secramine. They identified the first small molecules to inhibit the oxysterol-binding protein family, and these compounds are now used to study the role of these proteins at membrane contact sites.  Matt’s lab discovered that CDK8 and CDK19 are therapeutic targets for treatment of acute myeloid leukemia. These studies provided a deeper understanding of how these kinases regulate transcription in cancer and they led Matt’s lab to develop candidate small molecule therapeutic inhibitors of CDK8/19, which they out-licensed, resulting in one the largest upfront licensing payments in Harvard’s history. Due in-part to his lab’s studies, CDK8/19 inhibitors have now entered clinical trials for treatment of AML/MDS. Matt contributed to the founding of Infinity Pharmaceuticals and he has been an advisor to several large and small pharmaceutical companies. Matt has been the recipient of many awards for his research contributions including the Cope Scholar Award and the Sackler Prize in the Chemical Sciences.

Cameron Wheeler, PhD
Partner, Deerfield Management
Cameron Wheeler, PhD
Partner, Deerfield Management

Cameron is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2014. Prior to Deerfield, he worked for and on behalf of Eleven Biotherapeutics, Inc. as a director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals, Inc. and a Senior Associate at Third Rock Ventures, LLC. Cameron holds a PhD and SM in Biological Engineering and an SB in Mechanical Engineering from the Massachusetts Institute of Technology. 

Robert Jackson, MD
Independent Board Member
Robert Jackson, MD
Independent Board Member

Robert serves as an independent board member to Nuvalent. Since 2001, Robert held positions at Deerfield Management and served most recently as Partner and Chief Science Officer. Prior to Deerfield, Robert was a healthcare analyst at Janus Capital, and previously founded and managed a group ophthalmology practice. He holds an MD from West Virginia University and an MBA with distinction from the Wharton School at the University of Pennsylvania. He was a Cleveland Fellow at Case Western Reserve University, having spent a year at the Royal Melbourne Hospital in Australia. Robert completed his ophthalmology residency at Case Western Reserve University and was Chief Resident in his final year. 

Joseph Pearlberg, MD, PhD
VP of Scientific Affairs, Deerfield Management
Joseph Pearlberg, MD, PhD
VP of Scientific Affairs, Deerfield Management

Joseph is the Vice President of Scientific Affairs on the Biotherapeutics group at Deerfield and joined the Firm in 2017. Prior to Deerfield, Joseph was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Joseph worked as a Medical Director in the oncology unit of Sanofi. He received his MD at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his PhD in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Gary Gilliland, MD, PhD
Independent Board Member
Gary Gilliland, MD, PhD
Independent Board Member

Dr. Gary Gilliland is a physician-scientist who has made major contributions to understanding the genetic basis of blood diseases, particularly leukemia, and translated seminal findings into new, precision treatments that stop cancer while causing minimal side effects.

Dr. Gilliland led Fred Hutch from 2015 to early 2020. Among his achievements were strong growth and diversification of the faculty, an increase in the Hutch’s already-strong federal grant funding, a quadrupled endowment, adding the Lake Union Steam Plant to the campus as a nexus of data science and T-cell immunotherapy research, and new internal and external research collaborations. Through his leadership and vision, Gilliland reinforced the Hutch’s longstanding commitment to scientific excellence.

Among Gilliland’s major initiatives was the creation of the Hutch’s Integrated Research Centers, or IRCs, which promote collaboration among researchers across campus and throughout the Fred Hutch/University of Washington Cancer Consortium on high-impact, innovative projects.

Before he was named the Hutch’s fifth president, Dr. Gilliland spent 20 years at Harvard Medical School, led a breakthrough immunotherapy drug to market as senior vice president and global oncology franchise head at Merck and Co., and spearheaded a new model for personalized medicine within the University of Pennsylvania system.

Andrew A. F. Hack, MD, PhD
Managing Director, Bain Capital Life Sciences
Andrew A. F. Hack, MD, PhD
Managing Director, Bain Capital Life Sciences

Andrew is a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Previously, Andrew served as Chief Financial Officer of Editas Medicine, Inc.

Prior to joining Editas, Andrew was a portfolio manager at Millennium Management LLC, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Andrew served as a securities analyst for several healthcare-focused hedge funds and investment banks. Previously, Andrew was Director of Life Sciences of Reify Corporation, a life science tools and drug discovery company.

Andrew serves as a director of Affinivax, Inc., Allena Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc., BCLS Acquisition Corp., Dynavax Technologies, Inc., Imperative Care, Inc., JenaValve Technology, Inc., Mersana Therapeutics, Inc., and Xilio Therapeutics. Andrew received his M.D. and Ph.D. from the University of Chicago in molecular genetics and cell biology. 

Sapna Srivastava, PhD
Independent Board Member
Sapna Srivastava, PhD
Independent Board Member

Sapna Srivastava, Ph.D, has served as a member of Nuvalent’s board of directors since July 2021. Dr. Srivastava has over 20 years of experience as a senior executive in the biopharmaceutical industry. She has served as the Chief Financial Officer at eGenesis Bio since April 2021. From September 2017 to January 2019, Dr. Srivastava served as the Chief Financial and Strategy Officer at Abide Therapeutics, Inc., a biopharmaceutical company that was acquired by H. Lundbeck A/S in 2019. From April 2015 to December 2016, Dr. Srivastava served as the Chief Financial and Strategy Officer at Intellia Therapeutics, Inc. (NASDAQ: NTLA), a gene editing company. Previously, for nearly 15 years Dr. Srivastava was a senior biotechnology analyst at Goldman Sachs, Morgan Stanley, and ThinkEquity Partners, LLC. She began her career as a research associate at JP Morgan. Dr. Srivastava currently serves on the board of directors of Talaris Therapeutics, Inc. (NASDAQ: TALS), SQZ Biotechnologies Company (NYSE: SQZ), Aura Biosciences, and Asclepix Therapeutics, Inc. Dr. Srivastava holds a Ph.D. from New York University School of Medicine and a B.Sc. from St. Xavier’s College, University of Bombay.

D. Ross Camidge, MD, PhD
Director of Thoracic Oncology,
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Centre, Denver, USA
D. Ross Camidge, MD, PhD
Director of Thoracic Oncology,
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Centre, Denver, USA

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.
 
Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Lancet Oncology, and New England Journal of Medicine. He has received numerous awards including the Bonnie J. Addario International Lectureship Award and The Lung Cancer Foundation’s Breath Away From The Cure Award. Every year from 2017, he has been internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. In 2019 and 2020 he was ranked at the ‘World Expert’ level by Expertscape and recognized to be in the top 0.0043% of scholars writing about Lung Neoplasms over the past 10 years. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) – a collaborative network of 15 US and Canadian sites conducting trials in thoracic oncology, Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.

Matthew D. Shair, PhD
Founder, Head Scientific Advisor
Harvard University
Matthew D. Shair, PhD
Founder, Head Scientific Advisor
Harvard University

Matt is a world-leading chemical biologist and organic chemist who has made important contributions to the discovery of new therapeutic targets, to understanding their mechanism and to the development of small molecules to perturb their function. Matt conceived of Nuvalent and in 2017 he founded the company with Deerfield Management.

Matt is a Professor in the Department of Chemistry and Chemical Biology at Harvard University as well as an affiliate of the Broad Institute and the Harvard Stem Cell Institute. Matt and his lab at Harvard have made critical strides in target-oriented synthesis of complex molecules including syntheses of CP-263,114, longithorone and cortistatin A. His lab helped pioneer diversity-oriented synthesis and they were amongst the first to combine it with cell-based phenotypic screening to identify new compounds with novel activities, including the discovery of the Cdc42 inhibitor secramine. They identified the first small molecules to inhibit the oxysterol-binding protein family, and these compounds are now used to study the role of these proteins at membrane contact sites.  Matt’s lab discovered that CDK8 and CDK19 are therapeutic targets for treatment of acute myeloid leukemia. These studies provided a deeper understanding of how these kinases regulate transcription in cancer and they led Matt’s lab to develop candidate small molecule therapeutic inhibitors of CDK8/19, which they out-licensed, resulting in one the largest upfront licensing payments in Harvard’s history. Due in-part to his lab’s studies, CDK8/19 inhibitors have now entered clinical trials for treatment of AML/MDS. Matt contributed to the founding of Infinity Pharmaceuticals and he has been an advisor to several large and small pharmaceutical companies. Matt has been the recipient of many awards for his research contributions including the Cope Scholar Award and the Sackler Prize in the Chemical Sciences.

Michael Meyers, MD, PhD
Clinical Advisor
Syndax Pharmaceuticals
Michael Meyers, MD, PhD
Clinical Advisor
Syndax Pharmaceuticals

Michael currently is the Senior Vice President and Chief Medical Officer at Syndax Pharmaceuticals, where he has served since 2015.  Prior to joining Syndax, he held a number of senior R&D roles at Johnson & Johnson, including serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Michael also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc and worked in oncology clinical development at the Schering-Plough Research Institute. Prior, he was on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He received his MD and his PhD in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to Alpha Omega Alpha (the medical school honor society). He completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.

Pasi Jänne, MD, PhD
Clinical Advisor
Harvard Medical School,
Dana Farber Cancer Institute
Pasi Jänne, MD, PhD
Clinical Advisor
Harvard Medical School,
Dana Farber Cancer Institute

Pasi is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute.
His research combines laboratory-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer.  He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Pasi has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, the Bonnie J. Addario Lung Cancer Foundation, the American Association of Cancer Research , the European Society of Medical Oncology and the American Society of Clinical Oncology. In 2017 he was awarded an American Cancer Society Clinical Research Professorship. Pasi earned his Masters Degree in clinical investigation from Harvard University and his MD and PhD from the School of Medicine at the University of Pennsylvania. He completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston.

Aaron Hata, MD, PhD
Translational Research Advisor
Harvard Medical School, Mass General Cancer Center
Aaron Hata, MD, PhD
Translational Research Advisor
Harvard Medical School, Mass General Cancer Center

Aaron is a Medical Oncologist at Mass General Cancer Center in Boston and Assistant Professor of Medicine at Harvard Medical School. He is an accomplished scientist whose work focuses on advancing targeted therapies to benefit patients with lung cancer. His lab focuses on understanding the biological underpinnings of sensitivity and resistance to kinase inhibitor targeted therapies in lung cancers with specific genetic abnormalities (EGFR mutations, ALK translocations, KRAS mutations). Specifically, he is interested in discovering targetable mechanisms that promote tumor evolution and acquired drug resistance. Aaron earned his MD and PhD from Vanderbilt University School of Medicine, conducted his internship and residency in Internal Medicine at Brigham and Women’s Hospital, and completed Medical Oncology fellowship training at Dana Farber Cancer Institute and Massachusetts General Hospital.

Nancy Kohl, PhD
Translational Research Advisor
Nancy Kohl, PhD
Translational Research Advisor

Nancy is an accomplished cancer researcher with over three decades of oncology drug discovery and development experiencein big pharma, academic healthcare and biotech.  She joined Nuvalent as a Consultant in 2018 and provides guidance primarily in the areas of pharmacology and translational medicine.

Nancy spent over two decades at Merck Research Laboratories, working initially in the area of anti-viral drug discovery and then in oncology.  She held positions of increasing responsibility, ultimately playing a key role in establishing the Oncology group at Merck’s Boston laboratory and then leading that group. Her efforts contributed to the approval of two drugs, CRIXIVAN and ZOLINZA, and to the advancement of numerous compounds into clinical trials.  Following her tenure at Merck, she spent three years at Dana-Farber Cancer Institute, where she directed the Lurie Family Imaging Center and started a new integrative research center focused on evaluating experimental cancer therapies in relevant in vivo disease models to generate preclinical data to inform efficient clinical trials. Nancy then moved into the biotech sector, where she was Vice President, Biology at Blueprint Medicines.  Here she led a team of biologists in discovering and developing targeted kinase medicines for patients with genetically defined diseases, including the FDA-approved compound AYVAKIT.  She holds a PhD degree in biochemistry from Columbia University and did postdoctoral work at the MIT Center for Cancer Research.

Alexander Drilon, MD
Clinical Advisor
Memorial Sloan Kettering
Alexander Drilon, MD
Clinical Advisor
Memorial Sloan Kettering

Dr. Alexander Drilon is the Acting Chief of the Early Drug Development Service and a medical oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.

What Inspires Our Team: Core Values

Patient Impact

Kristen Andrews, principle scientist
Kristin Andrews, PhD
Computational Chemistry
Kristin explains how Nuvalent is driven by the needs of cancer patients to create safe, effective therapies that can make a difference in their lives.

Empowerment

Jason Kropp, Director Pharmaceutical Development
Jason Kropp
Pharmaceutical Development
Jason discusses how empowerment not only encompasses functional area decision making, but is key to building the Nuvalent company culture.

Collaboration

Anupong Tangpeerachaikul, Scientist
Anupong Tangpeerachaikul, PhD
Biology
Anupong shares why collaboration is at the core of Nuvalent’s mission, and how collaboration extends beyond the internal Nuvalent team.